Skip to main content
B

BrightPath Biotherapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 4594 ISIN · JP3274140007 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2025-11-21 Share Issue/Capital Cha…
Country JP Japan
Listing T 4594

About BrightPath Biotherapeutics Co., Ltd.

https://www.brightpathbio.com/english/

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Recent filings

Filing Released Lang Actions
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 1% confidence The document is a 'Yuka Shoken Todokesho' (Securities Registration Statement) filed with the Kanto Local Finance Bureau in Japan. It details the issuance of new share acquisition rights (stock options/warrants) by BrightPath Biotherapeutics Co., Ltd. This type of filing is a formal regulatory document required for capital raising activities, specifically falling under the category of share issuance and capital structure changes.
2025-11-21 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference another report type. H1 23
2025-11-14 Japanese
半期報告書－第23期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed by BrightPath Biotherapeutics Co., Ltd. with the Kanto Local Finance Bureau. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MD&A), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-14 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being submitted following the resolution of matters at the Annual General Meeting ('定時株主総会') held on June 19, 2025. Section 2 details the resolutions, specifically the election of four directors, and provides the voting results (votes for, against, abstentions, and approval percentage). This content perfectly matches the definition of reporting the official results from a shareholder meeting. The Japanese filing type '臨時報告書' (Extraordinary Report) often corresponds to filings reporting AGM/EGM results, which aligns with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA).
2025-06-20 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document is extremely short (662 characters) and contains a header structure typical of Japanese regulatory filings, specifically mentioning "有価証券報告書" (Annual Securities Report/10-K equivalent) and a confirmation statement ("確認書") signed by the CEO regarding its appropriateness based on the Financial Instruments and Exchange Act ("金融商品取引法"). This document is a formal certification or confirmation related to the accuracy of a previously filed or soon-to-be-filed comprehensive annual report (like a 10-K). Since it is a short confirmation document rather than the full report itself, and it relates directly to the accuracy of the annual filing, it is best classified as a Regulatory Filing (RNS) or potentially related to the Annual Report (10-K). Given the explicit mention of confirming the '有価証券報告書' (Securities Report), and the document being a short confirmation ('確認書'), it functions as a regulatory compliance document that doesn't fit the comprehensive 10-K definition. However, in the context of Japanese filings, this confirmation often accompanies the main filing. Since it is a specific compliance document that isn't a standard US form, and it's very short, RNS is a strong candidate. If we strictly interpret the definitions, it's a regulatory document that doesn't fit AR, ER, or IR. Given its nature as a formal confirmation required by law regarding the annual report, and its brevity, RNS (General regulatory announcement/fallback) is the most appropriate fit among the provided codes, as it is not the 10-K itself. FY 2025
2025-06-19 Japanese
内部統制報告書－第22期(2024/04/01－2025/03/31)
Governance Information Classification · 1% confidence The document header explicitly states the filing type as "内部統制報告書" (Internal Control Report) and cites the legal basis as Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項). The content discusses the framework, scope, criteria, procedures, and conclusion regarding the assessment of internal controls over financial reporting as of the fiscal year-end (March 31, 2025). This structure is characteristic of an Internal Control Report, which is typically filed alongside the Annual Report (10-K) in Japan, but based on the provided definitions, it most closely aligns with an Audit Report/Information (AR) as it deals with the assessment and results of internal controls, which is a form of assurance/audit-related reporting, distinct from the full 10-K or a simple earnings release. Given the specific nature of an internal control assessment report, 'AR' (Audit Report / Information) is the most appropriate fit among the choices, as it covers applied accounting principles and results of internal/regulatory stress tests/assessments.
2025-06-19 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.